GSK Plc announced on October 29 that it acquired Syndivia‘s preclinical antibody-drug conjugate (ADC).
Syndivia’s preclinical ADC is in development for the treatment of prostate cancer. Syndivia developed the prostate cancer drug hopeful using its GeminiMab conjugation technology, which the biotech claims can create a unique drug-to-antibody ratio hinge region site-specific ADC.
Syndivia is a French biotechnology company focused on the design and development of ADCs. Its proprietary technology enables the creation of next-generation ADCs with optimized therapeutic profiles, aiming to expand treatment options for patients with cancer.
GSK, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with its global headquarters in Brentford, England. According to its 2024 annual report, the company generated £31.376 billion (more than $41.3 billion USD) in revenue in 2024.
GSK will pay French biotech Syndivia £268 million ($357.37 million USD) for the preclinical asset’s global rights, a fee that includes an upfront payment, as well as development and commercial milestones.
According to data captured in the LevinPro HC database, this transaction represents the 112th Biotechnology transaction of 2025. There were 135 Biotechnology transactions announced in 2024, and 160 announced in 2023.
This is also GSK’s third acquisition of the year; previously, it purchased BP Asset IX, Inc., a pharmaceutical company, from Boston Pharmaceuticals for $1.2 billion and IDRx, a clinical-stage biopharmaceutical company, for $1 billion. Throughout 2024, GSK announced three acquisitions for a total of $1.43 billion in disclosed spending.
